Efficacy of Magnesium Trihydrate of Ursodeoxycholic Acid and Chenodeoxycholic Acid for Gallstone Dissolution: A Prospective Multicenter Trial
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Cholecystectomy is necessary for the treatment of symptomatic or complicated gallbladder (GB) stones, but oral litholysis with bile acids is an attractive alternative therapeutic option for asymptomatic or mildly symptomatic patients. This study was conducted to evaluate the efficacy of magnesium trihydrate of ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) on gallstone dissolution and to investigate improvements in gallstone-related symptoms. Methods: A prospective, multicenter, phase 4 clinical study to determine the efficacy of orally administered magnesium trihydrate of UDCA and CDCA was performed from January 2011 to June 2013. The inclusion criteria were GB stone diameter ≤15 mm, GB ejection fraction ≥50%, radiolucency on plain X-ray, and asymptomatic/mildly symptomatic patients. The patients were prescribed one capsule of magnesium trihydrate of UDCA and CDCA at breakfast and two capsules at bedtime for 6 months. The dissolution rate, response rate, and change in symptom score were evaluated. Results: A total of 237 subjects were enrolled, and 195 subjects completed the treatment. The dissolution rate was 45.1% and the response rate was 47.2% (92/195) after 6 months of administration of magnesium trihydrate of UDCA and CDCA. Only the stone diameter was significantly associated with the response rate. Both the symptom score and the number of patients with symptoms significantly decreased regardless of stone dissolution. Adverse events necessitating discontinuation of the drug, surgery, or endoscopic management occurred in 2.5% (6/237) of patients. Conclusions: Magnesium trihydrate of UDCA and CDCA is a well-tolerated bile acid that showed similar efficacy for gallstone dissolution and improvement of gallstone-related symptoms as that shown in previous studies.
Abstract
Background/Aims: Cholecystectomy is necessary for the treatment of symptomatic or complicated gallbladder (GB) stones, but oral litholysis with bile acids is an attractive alternative therapeutic option for asymptomatic or mildly symptomatic patients. This study was conducted to evaluate the efficacy of magnesium trihydrate of ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) on gallstone dissolution and to investigate improvements in gallstone-related symptoms. Methods: A prospective, multicenter, phase 4 clinical study to determine the efficacy of orally administered magnesium trihydrate of UDCA and CDCA was performed from January 2011 to June 2013. The inclusion criteria were GB stone diameter ≤15 mm, GB ejection fraction ≥50%, radiolucency on plain X-ray, and asymptomatic/mildly symptomatic patients. The patients were prescribed one capsule of magnesium trihydrate of UDCA and CDCA at breakfast and two capsules at bedtime for 6 months. The dissolution rate, response rate, and change in symptom score were evaluated. Results: A total of 237 subjects were enrolled, and 195 subjects completed the treatment. The dissolution rate was 45.1% and the response rate was 47.2% (92/195) after 6 months of administration of magnesium trihydrate of UDCA and CDCA. Only the stone diameter was significantly associated with the response rate. Both the symptom score and the number of patients with symptoms significantly decreased regardless of stone dissolution. Adverse events necessitating discontinuation of the drug, surgery, or endoscopic management occurred in 2.5% (6/237) of patients. Conclusions: Magnesium trihydrate of UDCA and CDCA is a well-tolerated bile acid that showed similar efficacy for gallstone dissolution and improvement of gallstone-related symptoms as that shown in previous studies.
참고문헌 (33)
- 장예림, "Changes in Demographic Features of Gallstone Disease: 30 Years of Surgically Treated Patients", Gut and Liver, 7(6), pp.719~724 (2013), 거트앤리버 발행위원회
- Portincasa P, "Cholesterol gallstone disease", Lancet, 368, pp.230~239 (2006)
- 정승욱, "비만과 담낭질환", 대한소화기학회지, 59(1), pp.27~34 (2012), 대한소화기학회
- Kim JW, "Has the prevalence of cholesterol gallstones increased in Korea? A preliminary single-center experience", J Dig Dis, 14, pp.559~563 (2013)
- Petroni ML, "Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group", Aliment Pharmacol Ther, 15, pp.123~128 (2001)
- Sleisenger MH, "Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management", pp.2010, Saunders
- May GR, "Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials", Aliment Pharmacol Ther, 7, pp.139~148 (1993)
- Raedsch R, "Ursodeoxycholic acid and gallstone calcification", Lancet, 2, pp.1296~ (1981)
- Bateson MC, "Calcification of radiolucent gall stone during treatment with ursodeoxycholic acid", Br Med J, 283, pp.645~646 (1981)
- Podda M, "Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: a comparison with ursodeoxycholic acid alone", Gastroenterology, 96, pp.222~229 (1989)
- Jazrawi RP, "Optimum bile acid treatment for rapid gall stone dissolution", Gut, 33, pp.381~386 (1992)
- Danzinger RG, "Dissolution of cholesterol gallstones by chenodeoxycholic acid", N Engl J Med, 286, pp.1~8 (1972)
- Bell GD, "Gallstone dissolution in man using chenodeoxycholic acid", Lancet, 2, pp.1213~1216 (1972)
- Nakagawa S, "Dissolution of cholesterol gallstones by ursodeoxycholic acid", Lancet, 2, pp.367~369 (1977)
- Tint GS, "Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones", Ann Intern Med, 97, pp.351~356 (1982)
- Diehl AK, "Epidemiology and natural history of gallstone disease", Gastroenterol Clin North Am, 20, pp.1~19 (1991)
- Kim MH, "Epidemiological study on Korean gallstone disease: a nationwide cooperative study", Dig Dis Sci, 44, pp.1674~1683 (1999)
- Trotman BW, "Evaluation of radiographic lucency or opaqueness of gallstones as a means of identifying cholesterol or pigment stones: correlation of lucency or opaqueness with calcium and mineral", Gastroenterology, 68, pp.1563~1566 (1975)
- Bell GD, "The value of radiology in predicting gallstone type when selecting patients for medical treatment", Gut, 16, pp.359~364 (1975)
- Baron RL, "CT evaluation of gallstones in vitro: correlation with chemical analysis", AJR Am J Roentgenol, 151, pp.1123~1128 (1988)
- Janowitz P, "Computed tomography evaluation of radiolucent gallstones in vivo", Gastrointest Radiol, 15, pp.58~60 (1990)
- Whiting MJ, "Chemical composition of gallstones resistant to dissolution therapy with chenodeoxycholic acid", Gut, 21, pp.1077~1081 (1980)
- Freilich HS, "Chemical and morphologic characteristics of cholesterol gallstones that failed to dissolve on chenodiol: the National Cooperative Gallstone Study", Gastroenterology, 91, pp.713~718 (1986)
- Kupfer RM, "Gallstone dissolution rate during chenic acid therapy: effect of bedtime administration plus low cholesterol diet", Dig Dis Sci, 27, pp.1025~1029 (1982)
- Lanzini A, "Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administration", Gastroenterology, 95, pp.1029~1035 (1988)
- Inoi J, "Effect of administration of ursodeoxycholic acid at bedtime on cholesterol saturation of hepatic bile in Japanese patients with gallstone", J Med Invest, 45, pp.115~122 (1998)
- Polli EE, "Treatment of radiolucent gallstones with CDCA or UDCA: a multicenter trial", Digestion, 22, pp.185~191 (1981)
- Meredith TJ, "Retrospective comparison of 'Cheno' and 'Urso' in the medical treatment of gallstones", Gut, 23, pp.382~389 (1982)
- Guarino MP, "Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones", Gut, 56, pp.815~820 (2007)
- Portincasa P, "Therapy of gallstone disease: what it was, what it is, what it will be", World J Gastrointest Pharmacol Ther, 3, pp.7~20 (2012)
- Tuncer I, "Effect of ursodeoxycholic acid alone and ursodeoxycholic acid plus domperidone on radiolucent gallstones and gallbladder contractility in humans", Gastroenterol Res Pract, 2012, pp.159438~ (2012)
- DiBaise JK, "Does gallbladder ejection fraction predict outcome after cholecystectomy for suspected chronic acalculous gallbladder dysfunction? A systematic review", Am J Gastroenterol, 98, pp.2605~2611 (2003)
- Stender S, "Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study", Hepatology, 58, pp.2133~2141 (2013)